dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Moura, David |
dc.contributor.author | Peña-Chilet, Maria |
dc.contributor.author | Cordero Varela, Juan Antonio |
dc.contributor.author | Alvarez Alegret, Ramiro |
dc.contributor.author | AGRA PUJOL, CAROLINA |
dc.contributor.author | Izquierdo, Francisco |
dc.contributor.author | Romagosa, Cleofé |
dc.contributor.author | Valverde, Claudia María |
dc.date.accessioned | 2021-12-16T07:03:26Z |
dc.date.available | 2021-12-16T07:03:26Z |
dc.date.issued | 2021-12 |
dc.identifier.citation | Moura DS, Peña‐Chilet M, Cordero Varela JA, Alvarez‐Alegret R, Agra‐Pujol C, Izquierdo F, et al. A DNA damage repair gene‐associated signature predicts responses of patients with advanced soft‐tissue sarcoma to treatment with trabectedin. Mol Oncol. 2021 Dec;15(12):3691–705. |
dc.identifier.issn | 3691–3705 |
dc.identifier.uri | https://hdl.handle.net/11351/6693 |
dc.description | Signatura genètica; Biomarcadors predictius; Trabectedina |
dc.description.sponsorship | This study was funded by the Spanish Group for Research on Sarcoma (GEIS) and partially by PharmaMar. The authors would like to thank the GEIS data center for data management. The authors also thank the donors and the Hospital Universitario Virgen del Rocío—Instituto de Biomedicina de Sevilla Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT17/0015/0041) for part of the human specimens used in this study. David S. Moura is recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155). |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Molecular Oncology;15(12) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Sarcoma - Tractament |
dc.subject | ADN - Reparació |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Sarcoma |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | DNA Repair |
dc.subject.mesh | Treatment Outcome |
dc.title | A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/1878-0261.12996 |
dc.subject.decs | sarcoma |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | reparación del ADN |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1002/1878-0261.12996 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Moura DS, Cordero Varela JA] Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Spain. [Peña-Chilet M] Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Spain. Clinical Bioinformatics Area, Fundacion Progreso y Salud (FPS), CDCA, Hospital Virgen del Rocio, Seville, Spain. Bioinformatics in Rare Diseases (BiER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocio, Seville, Spain. [Alvarez-Alegret R] Pathology Department, Miguel Servet University Hospital, Zaragoza, Spain. [Agra-Pujol C] Pathology Department, Gregorio Maranon University Hospital, Madrid, Spain. [Izquierdo F] Pathological Anatomy Service, Complejo Asistencial Universitario de Leon, Spain. [Romagosa C] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Valverde] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 33983674 |
dc.identifier.wos | 000668189600001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/CD20%2F00155 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |